Effective Date:

Monday, November 03, 2014

Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, November 03, 2014

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
7620SP	17-Hydroxyprogesterone, Serum/Plasma			•					
7641SP	Adrenal Insufficiency Panel, Serum/Plasma			•				•	
7632SP	Aldosterone, Serum/Plasma			•				•	
7642SP	Aldosteronism / Hypertension Panel, Serum/Plasma							•	
7622SP	Androstenedione, Serum/Plasma			•					
7651SP	Dihydrotestosterone (DHT) Panel, Serum/Plasma							•	
8075B	Drug Impaired Driving/DRE Toxicology Expanded Drug Screen Add-On, Blood (Forensic)							•	
8075SP	Drug Impaired Driving/DRE Toxicology Expanded Drug Screen Add-On, Serum/Plasma (Forensic)							•	
8075U	Drug Impaired Driving/DRE Toxicology Expanded Drug Screen Add-On, Urine (Forensic)							•	
1876B	Drug Screen, Expanded, Blood							•	
1876U	Drug Screen, Expanded, Urine							•	
1450SP	Drug-Facilitated Sexual Assault Screen, Serum/Plasma (Forensic)							•	
1452B	Drug-Facilitated Sexual Assault Survey 2, Blood (Forensic)							•	
1452U	Drug-Facilitated Sexual Assault Survey 2, Urine (Forensic)							•	
7635SP	Estriol (E3), Serum/Plasma			•					
7633SP	Estrone (E1), Serum/Plasma			•					
1866B	GC/MS Drug Screen, Blood (Forensic)							•	
1866FL	GC/MS Drug Screen, Fluid (Forensic)							•	
1866SP	GC/MS Drug Screen, Serum/Plasma (Forensic)							•	
1866TI	GC/MS Drug Screen, Tissue (Forensic)							•	
1866U	GC/MS Drug Screen, Urine (Forensic)							•	
5696B	Methylenedioxymethamphetamine and Metabolite Confirmation, Blood		•	•					
5696SP	Methylenedioxymethamphetamine and Metabolite Confirmation, Serum/Plasma		•	•					
5696U	Methylenedioxymethamphetamine and Metabolite Confirmation, Urine		•	•					
9293B	Methylenedioxymethamphetamine and Metabolite Screen, Blood		•	•				•	
9293SP	Methylenedioxymethamphetamine and Metabolite Screen, Serum/Plasma		•	•				•	
9293U	Methylenedioxymethamphetamine and Metabolite Screen, Urine		•	•				•	

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
54293B	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic)	•		•				•	
54293SP	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation (Drug Impaired Driving/DRE Toxicology), Serum/Plasma (Forensic)	•		•				•	
52093B	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Blood (Forensic)	•		•				•	
53093B	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Blood (Forensic)	•		•				•	
52093FL	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Fluid (Forensic)	•						•	
53093FL	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Fluid (Forensic)	•		•				•	
52093SP	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Serum/Plasma (Forensic)	•		•				•	
53093SP	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Serum/Plasma (Forensic)	•		•				•	
3265B	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite, Blood	•		•				•	
3265SP	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite, Serum/Plasma	•		•				•	
54293U	Oxcarbazepine/Eslicarbazepine as Metabolite Confirmation (Drug Impaired Driving/DRE Toxicology), Urine (Forensic)	•						•	
52093TI	Oxcarbazepine/Eslicarbazepine as Metabolite Confirmation, Tissue (Forensic)	•		•				•	
53093TI	Oxcarbazepine/Eslicarbazepine as Metabolite Confirmation, Tissue (Forensic)	•		•				•	
52093U	Oxcarbazepine/Eslicarbazepine as Metabolite Confirmation, Urine (Forensic)	•						•	
53093U	Oxcarbazepine/Eslicarbazepine as Metabolite Confirmation, Urine (Forensic)	•						•	
8063B	Postmortem Toxicology - Basic to Expanded Upgrade, Blood (Forensic)							•	
8063FL	Postmortem Toxicology - Basic to Expanded Upgrade, Fluid (Forensic)							•	
8063SP	Postmortem Toxicology - Basic to Expanded Upgrade, Serum/Plasma (Forensic)							•	

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
8063TI	Postmortem Toxicology - Basic to Expanded Upgrade, Tissue (Forensic)							•	
8063U	Postmortem Toxicology - Basic to Expanded Upgrade, Urine (Forensic)							•	
8062B	Postmortem Toxicology - Expanded w/o Alcohol, Blood (Forensic)							•	
8062U	Postmortem Toxicology - Expanded w/o Alcohol, Urine (Forensic)							•	
8042B	Postmortem Toxicology - Expanded with Vitreous Alcohol Confirmation, Blood (Forensic)							•	
10052B	Postmortem Toxicology - Expanded with Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)							•	
8057B	Postmortem Toxicology - Expanded with Vitreous Alcohol Confirmation, Blood - University of MI (CSA)							•	
8052B	Postmortem Toxicology - Expanded, Blood (Forensic)							•	
8052FL	Postmortem Toxicology - Expanded, Fluid (Forensic)							•	
8052SP	Postmortem Toxicology - Expanded, Serum/Plasma (Forensic)							•	
8052TI	Postmortem Toxicology - Expanded, Tissue (Forensic)							•	
8052U	Postmortem Toxicology - Expanded, Urine (Forensic)							•	
8043B	Postmortem Toxicology - Expert with Vitreous Alcohol Confirmation, Blood (Forensic)							•	
10092B	Postmortem Toxicology - Expert with Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)							•	
8092B	Postmortem Toxicology - Expert, Blood (Forensic)							•	
8092FL	Postmortem Toxicology - Expert, Fluid (Forensic)							•	
8092SP	Postmortem Toxicology - Expert, Serum/Plasma (Forensic)							•	
8092TI	Postmortem Toxicology - Expert, Tissue (Forensic)							•	
8092U	Postmortem Toxicology - Expert, Urine (Forensic)							•	
4177B	Postmortem Toxicology - SIDS Screen, Blood (Forensic)							•	
4187B	Postmortem Toxicology - SIDS Screen, Blood (Forensic)							•	
4187FL	Postmortem Toxicology - SIDS Screen, Fluid (Forensic)							•	
4177TI	Postmortem Toxicology - SIDS Screen, Tissue (Forensic)							•	

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
4187TI	Postmortem Toxicology - SIDS Screen, Tissue (Forensic)							•	
4177U	Postmortem Toxicology - SIDS Screen, Urine (Forensic)							•	
4187U	Postmortem Toxicology - SIDS Screen, Urine (Forensic)							•	
7671SP	Steroids Panel, Serum/Plasma (CSA)							•	
7606SP	Testosterone, Free and Total (CSA), Serum/Plasma							•	
7610SP	Testosterone, Free and Total (CSA), Serum/Plasma							•	
7601SP	Testosterone, Free and Total, Serum/Plasma							•	
7613SP	Testosterone, Free, Total and Bioavailable (CSA), Serum/Plasma							•	
7614SP	Testosterone, Free, Total and Bioavailable (CSA), Serum/Plasma							•	
7602SP	Testosterone, Free, Total and Bioavailable, Serum/Plasma							•	
7603SP	Testosterone, Total and Bioavailable, Serum/Plasma							•	
7600SP	Testosterone, Total, Serum/Plasma							•	
8102B	Therapeutic and Abused Drugs with Alcohol Screen, Blood (Forensic)							•	
8102FL	Therapeutic and Abused Drugs with Alcohol Screen, Fluid (Forensic)							•	
8102SP	Therapeutic and Abused Drugs with Alcohol Screen, Serum/Plasma (Forensic)							•	
8102TI	Therapeutic and Abused Drugs with Alcohol Screen, Tissue (Forensic)							•	
8102U	Therapeutic and Abused Drugs with Alcohol Screen, Urine (Forensic)							•	

Test Updates

Test Changes

7620SP 17-Hydroxyprogesterone, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.

Specimen Requirements: 0.5 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Green top tube (Sodium Heparin), Lavender top tube (EDTA), Light Green top tube (Lithium Heparin), Pink top tube (EDTA), Polymer gel separation tube (SST or PST), Red top tube (no additive)
Light Protection: Not Required
Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: None

7641SP Adrenal Insufficiency Panel, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Reference Comment was changed.

Specimen Requirements: 2 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Green top tube (Sodium Heparin), Lavender top tube (EDTA), Light Green top tube (Lithium Heparin), Pink top tube (EDTA), Polymer gel separation tube (SST or PST), Red top tube (no additive)
Light Protection: Not Required
Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature.
Scope of Analysis: LC-MS/MS (82088): Aldosterone
Method (CPT Code) LC-MS/MS (83789): Dehydroepiandrosterone, Cortisol, 11-Deoxycortisol

Compound Name	Units	Reference Comment
Aldosterone	ng/dL	Reference Intervals for patients: Up to 7 years: Less than 19.8 ng/dL Age 8 - 17 years: Less than 20.1 ng/dL Reference Intervals for Females age 18 years and above: 0.8 - 24.0 ng/dL Reference Intervals for Males age 18 years and above: 0.7 - 28.6 ng/dL

7632SP Aldosterone, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Reference Comment was changed.

Test Updates

Test Changes

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Green top tube (Sodium Heparin), Lavender top tube (EDTA), Red top tube (no additive)
Light Protection:	Not Required
Special Handling:	Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (82088): Aldosterone

Compound Name	Units	Reference Comment
Aldosterone	ng/dL	Reference Intervals for patients: Up to 7 years: Less than 19.8 ng/dL Age 8 - 17 years: Less than 20.1 ng/dL Reference Intervals for Females age 18 years and above: 0.8 - 24.0 ng/dL Reference Intervals for Males age 18 years and above: 0.7 - 28.6 ng/dL

7642SP Aldosteronism / Hypertension Panel, Serum/Plasma

Summary of Changes:	Reference Comment was changed.

Scope of Analysis: Method (CPT Code)	LC-MS/MS (82088): Aldosterone LC-MS/MS (82528): Corticosterone

Compound Name	Units	Reference Comment
Aldosterone	ng/dL	Reference Intervals for patients: Up to 7 years: Less than 19.8 ng/dL Age 8 - 17 years: Less than 20.1 ng/dL Reference Intervals for Females age 18 years and above: 0.8 - 24.0 ng/dL Reference Intervals for Males age 18 years and above: 0.7 - 28.6 ng/dL

7622SP Androstenedione, Serum/Plasma

Summary of Changes:	Specimen Requirements (Specimen Container) were changed.

Test Updates

Test Changes

Specimen Requirements:	0.5 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Green top tube (Sodium Heparin), Lavender top tube (EDTA), Light Green top tube (Lithium Heparin), Pink top tube (EDTA), Polymer gel separation tube (SST or PST), Red top tube (no additive)
Light Protection:	Not Required
Special Handling:	Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature.

7651SP Dihydrotestosterone (DHT) Panel, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (82671): Dihydrotestosterone
Method (CPT Code) LC-MS/MS (82671): Testosterone, Total

Compound Name	Units	Reference Comment
Testosterone, Total	ng/dL	Reference Intervals for Males: Up to 1 month: 75-400 ng/dL Age 1-5 months: 14-363 ng/dL Age 6-24 months: Less than 37 ng/dL Age 2-3 years: Less than 15 ng/dL Age 4-5 years: Less than 19 ng/dL Age 6-7 years: Less than 13 ng/dL Age 8-9 years: 2-8 ng/dL Age 10-11 years: 2-165 ng/dL Age 12-13 years: 3-619 ng/dL Age 14-15 years: 31-733 ng/dL Age 16-17 years: 158-826 ng/dL Age 18-39 years: 300-1080 ng/dL Age 40-59 years: 300-890 ng/dL Age 60 years and above: 300-720 ng/dL Premature (26-28 weeks): 59-125 ng/dL Premature (29-35 weeks): 37-198 ng/dL Tanner Stage I: 2-15 ng/dL Tanner Stage II: 3-303 ng/dL Tanner Stage III: 10-851 ng/dL Tanner Stage IV-V: 162-847 ng/dL Reference Intervals for Females: Up to 1 month: 20-64 ng/dL Age 1-5 months: Less than 20 ng/dL Age 6-24 months: Less than 9 ng/dL Age 2-3 years: Less than 20 ng/dL Age 4-5 years: Less than 30 ng/dL Age 6-7 years: Less than 7 ng/dL

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		Age 8-9 years: 1-11 ng/dL Age 10-11 years: 3-32 ng/dL Age 12-13 years: 6-50 ng/dL Age 14-15 years: 6-52 ng/dL Age 16-17 years: 9-58 ng/dL Age 18-59 years: 9-55 ng/dL Age 60 years and above: 5-32 ng/dL Premature (26-28 weeks): 5-16 ng/dL Premature (29-35 weeks): 5-22 ng/dL Premenopausal (Greater than 18 years): 9-55 ng/dL Postmenopausal: 5-32 ng/dL Tanner Stage I: 2-17 ng/dL Tanner Stage II: 5-40 ng/dL Tanner Stage III: 10-63 ng/dL Tanner Stage IV-V: 11-62 ng/dL

8075B Drug Impaired Driving/DRE Toxicology Expanded Drug Screen Add-On, Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8075SP Drug Impaired Driving/DRE Toxicology Expanded Drug Screen Add-On, Serum/Plasma (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8075U Drug Impaired Driving/DRE Toxicology Expanded Drug Screen Add-On, Urine (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

1876B Drug Screen, Expanded, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

1876U Drug Screen, Expanded, Urine

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

1450SP Drug-Facilitated Sexual Assault Screen, Serum/Plasma (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

1452B Drug-Facilitated Sexual Assault Survey 2, Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

1452U Drug-Facilitated Sexual Assault Survey 2, Urine (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

7635SP Estriol (E3), Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.

Specimen Requirements: 0.5 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Green top tube (Sodium Heparin), Lavender top tube (EDTA), Light Green top tube (Lithium Heparin), Pink top tube (EDTA), Polymer gel separation tube (SST or PST), Red top tube (no additive)
Light Protection: Not Required
Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: None

7633SP Estrone (E1), Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.

Specimen Requirements: 0.5 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Green top tube (Sodium Heparin), Lavender top tube (EDTA), Light Green top tube (Lithium Heparin), Pink top tube (EDTA), Polymer gel separation tube (SST or PST), Red top tube (no additive)
Light Protection: Not Required
Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: None

1866B GC/MS Drug Screen, Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

1866FL GC/MS Drug Screen, Fluid (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

1866SP GC/MS Drug Screen, Serum/Plasma (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

1866TI GC/MS Drug Screen, Tissue (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/g	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

1866U GC/MS Drug Screen, Urine (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

5696B Methylenedioxymethamphetamine and Metabolite Confirmation, Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Methods/CPT Codes were changed [LC-MS/MS (83789)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): LC-MS/MS (83789): MDMA, MDA

5696SP Methylenedioxymethamphetamine and Metabolite Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Methods/CPT Codes were changed [LC-MS/MS (83789)]

Test Updates

Test Changes

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): MDMA, MDA

5696U Methylenedioxymethamphetamine and Metabolite Confirmation, Urine

Summary of Changes:	Specimen Requirements (Specimen Container) were changed. Methods/CPT Codes were changed [LC-MS/MS (83789)]

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): MDMA, MDA

9293B Methylenedioxymethamphetamine and Metabolite Screen, Blood

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Reference Comment was changed. Methods/CPT Codes were changed [LC/TOF-MS (80100)]

Specimen Requirements:	3 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC/TOF-MS (80100): MDA, MDMA

Test Updates

Test Changes

Compound Name	Units	Reference Comment
MDA	ng/mL	[Reference comment removed]
MDMA	ng/mL	[Reference comment removed]

9293SP Methylenedioxymethamphetamine and Metabolite Screen, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC/TOF-MS (80100)]

Specimen Requirements: 3 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Scope of Analysis: Method (CPT Code) LC/TOF-MS (80100): MDA, MDMA

Compound Name	Units	Reference Comment
MDA	ng/mL	[Reference comment removed]
MDMA	ng/mL	[Reference comment removed]

9293U Methylenedioxymethamphetamine and Metabolite Screen, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC/TOF-MS (80100)]

Specimen Requirements: 2 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code) LC/TOF-MS (80100): MDA, MDMA

Test Updates

Test Changes

Compound Name	Units	Reference Comment
MDA	ng/mL	[Reference comment removed]
MDMA	ng/mL	[Reference comment removed]

54293B Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic)

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): HPLC (80183): 10-Hydroxycarbazepine

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

54293SP Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation (Drug Impaired Driving/DRE Toxicology), Serum/Plasma (Forensic)

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Reference Comment was changed.

Test Changes

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Scope of Analysis: Method (CPT Code)	HPLC (80183): 10-Hydroxycarbazepine

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

52093B Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Blood (Forensic)

Summary of Changes:	Test Name was changed. Specimen Requirements (Specimen Container) were changed. Reference Comment was changed.

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	HPLC (80183): 10-Hydroxycarbazepine

Test Updates

Test Changes

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

53093B Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Blood (Forensic)

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): HPLC (80183): 10-Hydroxycarbazepine

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

52093FL Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Fluid (Forensic)

Test Updates

Test Changes

Summary of Changes: Test Name was changed.
Reference Comment was changed.

Scope of Analysis: HPLC (82491): 10-Hydroxycarbazepine
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

53093FL Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Fluid (Forensic)

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Reference Comment was changed.

Specimen Requirements: 2 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: HPLC (82491): 10-Hydroxycarbazepine
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

52093SP Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Serum/Plasma (Forensic)

Test Updates

Test Changes

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Scope of Analysis: Method (CPT Code) HPLC (80183): 10-Hydroxycarbazepine

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

53093SP Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).

Test Updates

Test Changes

Scope of Analysis: HPLC (80183): 10-Hydroxycarbazepine
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

3265B Oxcarbazepine/Eslicarbazepine Acetate as Metabolite, Blood

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: HPLC (80183): 10-Hydroxycarbazepine
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

3265SP Oxcarbazepine/Eslicarbazepine Acetate as Metabolite, Serum/Plasma

Test Updates

Test Changes

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Scope of Analysis: Method (CPT Code) HPLC (80183): 10-Hydroxycarbazepine

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

54293U Oxcarbazepine/Eslicarbazepine as Metabolite Confirmation (Drug Impaired Driving/DRE Toxicology), Urine (Forensic)

Summary of Changes: Test Name was changed.
Reference Comment was changed.

Scope of Analysis: Method (CPT Code) HPLC (80183): 10-Hydroxycarbazepine

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

Test Updates

Test Changes

52093TI Oxcarbazepine/Eslicarbazepine as Metabolite Confirmation, Tissue (Forensic)

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Reference Comment was changed.

Specimen Requirements: 10 g Tissue
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): HPLC (80183, 80103): 10-Hydroxycarbazepine

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/g	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

53093TI Oxcarbazepine/Eslicarbazepine as Metabolite Confirmation, Tissue (Forensic)

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Reference Comment was changed.

Specimen Requirements: 10 g Tissue
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): HPLC (80183, 80103): 10-Hydroxycarbazepine

Test Updates

Test Changes

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/g	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

52093U Oxcarbazepine/Eslicarbazepine as Metabolite Confirmation, Urine (Forensic)

Summary of Changes: Test Name was changed.
Reference Comment was changed.

Scope of Analysis: Method (CPT Code): HPLC (80183): 10-Hydroxycarbazepine

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

53093U Oxcarbazepine/Eslicarbazepine as Metabolite Confirmation, Urine (Forensic)

Summary of Changes: Test Name was changed.
Reference Comment was changed.

Scope of Analysis: Method (CPT Code): HPLC (80183): 10-Hydroxycarbazepine

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®). Substance(s) known to interfere with the identity and/or quantity of the reported result: Felbamate.

8063B Postmortem Toxicology - Basic to Expanded Upgrade, Blood (Forensic)

Test Updates

Test Changes

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8063FL Postmortem Toxicology - Basic to Expanded Upgrade, Fluid (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

GC/MS (80100):
GC/MS (80100): 10-Hydroxycarbazepine, 7-Amino Flunitrazepam, Acetaminophen, Alfentanil, Amitriptyline, Amoxapine, Atomoxetine, Atropine, Benztropine, Brompheniramine, Bupivacaine, Bupropion, Bupropion Metabolite, Buspirone, Butorphanol, Caffeine, Carbamazepine, Carbinoxamine, Carbromal, Carisoprodol, Cetirizine, Chlorpheniramine, Chlorpromazine, Chlorpropamide, Citalopram / Escitalopram, Clomipramine, Clozapine, Cotinine, Cyclizine, Cyclobenzaprine, Desipramine, Desmethylclomipramine, Desmethyldoxepin, Dicyclomine, Diltiazem, Diphenhydramine, Diphenoxylate, Donepezil, Doxepin, Doxylamine, Duloxetine, Ethosuximide, Ethotoin, Ethylmorphine, Etomidate, Fentanyl, Flunitrazepam, Fluoxetine, Fluvoxamine, Guaifenesin, Haloperidol, Hydroxybupropion, Hydroxychloroquine, Hydroxyzine, Ibuprofen, Imipramine, Ketamine, Lamotrigine, Levetiracetam, Lidocaine, Maprotiline, Meclizine, Mefloquine, Meperidine, Mephenytoin, Mephobarbital, Mepivacaine, Meprobamate, Mesoridazine, Methapyrilene, Methaqualone, Methcathinone, Methocarbamol, Methorphan, Methylphenidate, Metoclopramide, Metoprolol, Mirtazapine, Monoethylglycinexylidide (MEGX), N-Acetylprocainamide, Naproxen, Nicotine, Nifedipine, Norclozapine, Norfentanyl, Norfluoxetine, Norketamine, Normeperidine, Normethsuximide, Nortriptyline, O-Desmethylvenlafaxine, Olanzapine, Orphenadrine, Papaverine, Paroxetine, Pentazocine, Phenacetin, Pheniramine, Phensuximide, Phenytoin, Primidone, Procainamide, Prochlorperazine, Promazine, Promethazine, Quetiapine, Quinidine, Quinine, Sertraline, Strychnine, Sufentanil, Theobromine, Theophylline, Thiopental, Thioridazine, Thiothixene, Ticlopidine, Tiletamine, Tramadol, Tranylcypromine, Trazodone, Trihexyphenidyl, Venlafaxine, Verapamil, Warfarin, Xylazine, Zaleplon, Zolazepam, Zolpidem, Other Findings

Test Updates

Test Changes

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8063SP Postmortem Toxicology - Basic to Expanded Upgrade, Serum/Plasma (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8063TI Postmortem Toxicology - Basic to Expanded Upgrade, Tissue (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

GC/MS (80100, 80103):
GC/MS (80100, 80103): 10-Hydroxycarbazepine, 7-Amino Flunitrazepam, Acetaminophen, Alfentanil, Amitriptyline, Amoxapine, Atomoxetine, Atropine, Benztropine, Brompheniramine, Bupivacaine, Bupropion, Bupropion Metabolite, Buspirone, Butorphanol, Caffeine, Carbamazepine, Carbinoxamine, Carbromal, Carisoprodol, Cetirizine, Chlorpheniramine, Chlorpromazine, Chlorpropamide, Citalopram / Escitalopram, Clomipramine, Clozapine, Cotinine, Cyclizine, Cyclobenzaprine, Desipramine, Desmethylclomipramine, Desmethyldoxepin, Dicyclomine, Diltiazem, Diphenhydramine, Diphenoxylate, Donepezil, Doxepin, Doxylamine, Duloxetine, Ethosuximide, Ethotoin, Ethylmorphine, Etomidate, Fentanyl, Flunitrazepam, Fluoxetine, Fluvoxamine, Guaifenesin, Haloperidol, Hydroxybupropion, Hydroxychloroquine, Hydroxyzine, Ibuprofen, Imipramine, Ketamine, Lamotrigine, Levetiracetam, Lidocaine, Maprotiline, Meclizine, Mefloquine, Meperidine, Mephenytoin, Mephobarbital, Mepivacaine, Meprobamate, Mesoridazine, Methapyrilene, Methaqualone, Methcathinone, Methocarbamol, Methorphan, Methylphenidate, Metoclopramide, Metoprolol, Mirtazapine, Monoethylglycinexylidide (MEGX), N-Acetylprocainamide, Naproxen, Nicotine, Nifedipine, Norclozapine, Norfentanyl, Norfluoxetine, Norketamine, Normeperidine,

Test Updates

Test Changes

Normethsuximide, Nortriptyline, O-Desmethylvenlafaxine, Olanzapine, Orphenadrine, Papaverine, Paroxetine, Pentazocine, Phenacetin, Pheniramine, Phensuximide, Phenytoin, Primidone, Procainamide, Prochlorperazine, Promazine, Promethazine, Quetiapine, Quinidine, Quinine, Sertraline, Strychnine, Sufentanil, Theobromine, Theophylline, Thiopental, Thioridazine, Thiothixene, Ticlopidine, Tiletamine, Tramadol, Tranylcypromine, Trazodone, Trihexyphenidyl, Venlafaxine, Verapamil, Warfarin, Xylazine, Zaleplon, Zolazepam, Zolpidem, Other Findings

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/g	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8063U Postmortem Toxicology - Basic to Expanded Upgrade, Urine (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8062B Postmortem Toxicology - Expanded w/o Alcohol, Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8062U Postmortem Toxicology - Expanded w/o Alcohol, Urine (Forensic)

Test Updates

Test Changes

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

10052B Postmortem Toxicology - Expanded with Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8042B Postmortem Toxicology - Expanded with Vitreous Alcohol Confirmation, Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8057B Postmortem Toxicology - Expanded with Vitreous Alcohol Confirmation, Blood - University of MI (CSA)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8052B Postmortem Toxicology - Expanded, Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8052FL Postmortem Toxicology - Expanded, Fluid (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8052SP Postmortem Toxicology - Expanded, Serum/Plasma (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8052TI Postmortem Toxicology - Expanded, Tissue (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/g	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8052U Postmortem Toxicology - Expanded, Urine (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

10092B Postmortem Toxicology - Expert with Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8043B Postmortem Toxicology - Expert with Vitreous Alcohol Confirmation, Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8092B Postmortem Toxicology - Expert, Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8092FL Postmortem Toxicology - Expert, Fluid (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8092SP Postmortem Toxicology - Expert, Serum/Plasma (Forensic)

Test Updates

Test Changes

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8092TI Postmortem Toxicology - Expert, Tissue (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/g	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8092U Postmortem Toxicology - Expert, Urine (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

4177B Postmortem Toxicology - SIDS Screen, Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

4187B Postmortem Toxicology - SIDS Screen, Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

4187FL Postmortem Toxicology - SIDS Screen, Fluid (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

4177TI Postmortem Toxicology - SIDS Screen, Tissue (Forensic)

Test Updates

Test Changes

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/g	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

4187TI Postmortem Toxicology - SIDS Screen, Tissue (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/g	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

4177U Postmortem Toxicology - SIDS Screen, Urine (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

4187U Postmortem Toxicology - SIDS Screen, Urine (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

7671SP Steroids Panel, Serum/Plasma (CSA)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (83789): Cortisol, Dehydroepiandrosterone, Dehydroepiandrosterone Sulfate, 11-Deoxycortisol, Androstenedione, 17-Hydroxyprogesterone, Progesterone
Method (CPT Code) LC-MS/MS (83789): Testosterone, Total

Compound Name	Units	Reference Comment
Testosterone, Total	ng/dL	Reference Intervals for Males: Up to 1 month: 75-400 ng/dL Age 1-5 months: 14-363 ng/dL Age 6-24 months: Less than 37 ng/dL Age 2-3 years: Less than 15 ng/dL Age 4-5 years: Less than 19 ng/dL Age 6-7 years: Less than 13 ng/dL Age 8-9 years: 2-8 ng/dL Age 10-11 years: 2-165 ng/dL Age 12-13 years: 3-619 ng/dL Age 14-15 years: 31-733 ng/dL Age 16-17 years: 158-826 ng/dL Age 18-39 years: 300-1080 ng/dL Age 40-59 years: 300-890 ng/dL Age 60 years and above: 300-720 ng/dL Premature (26-28 weeks): 59-125 ng/dL Premature (29-35 weeks): 37-198 ng/dL Tanner Stage I: 2-15 ng/dL Tanner Stage II: 3-303 ng/dL Tanner Stage III: 10-851 ng/dL Tanner Stage IV-V: 162-847 ng/dL Reference Intervals for Females: Up to 1 month: 20-64 ng/dL Age 1-5 months: Less than 20 ng/dL Age 6-24 months: Less than 9 ng/dL Age 2-3 years: Less than 20 ng/dL Age 4-5 years: Less than 30 ng/dL Age 6-7 years: Less than 7 ng/dL Age 8-9 years: 1-11 ng/dL Age 10-11 years: 3-32 ng/dL Age 12-13 years: 6-50 ng/dL

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		Age 14-15 years: 6-52 ng/dL Age 16-17 years: 9-58 ng/dL Age 18-59 years: 9-55 ng/dL Age 60 years and above: 5-32 ng/dL Premature (26-28 weeks): 5-16 ng/dL Premature (29-35 weeks): 5-22 ng/dL Premenopausal (Greater than 18 years): 9-55 ng/dL Postmenopausal: 5-32 ng/dL Tanner Stage I: 2-17 ng/dL Tanner Stage II: 5-40 ng/dL Tanner Stage III: 10-63 ng/dL Tanner Stage IV-V: 11-62 ng/dL

7606SP Testosterone, Free and Total (CSA), Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (84403): Testosterone, Total, Testosterone, Free (calculated),
Method (CPT Code) Testosterone, % Free (calculated)
Colorimetry (None):
IA (None): Sex Hormone Binding Globulin

Compound Name	Units	Reference Comment
Testosterone, Total	ng/dL	Reference Intervals for Males: Up to 1 month: 75-400 ng/dL Age 1-5 months: 14-363 ng/dL Age 6-24 months: Less than 37 ng/dL Age 2-3 years: Less than 15 ng/dL Age 4-5 years: Less than 19 ng/dL Age 6-7 years: Less than 13 ng/dL Age 8-9 years: 2-8 ng/dL Age 10-11 years: 2-165 ng/dL Age 12-13 years: 3-619 ng/dL Age 14-15 years: 31-733 ng/dL Age 16-17 years: 158-826 ng/dL Age 18-39 years: 300-1080 ng/dL Age 40-59 years: 300-890 ng/dL Age 60 years and above: 300-720 ng/dL Premature (26-28 weeks): 59-125 ng/dL Premature (29-35 weeks): 37-198 ng/dL Tanner Stage I: 2-15 ng/dL Tanner Stage II: 3-303 ng/dL Tanner Stage III: 10-851 ng/dL Tanner Stage IV-V: 162-847 ng/dL Reference Intervals for Females:

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		Up to 1 month: 20-64 ng/dL Age 1-5 months: Less than 20 ng/dL Age 6-24 months: Less than 9 ng/dL Age 2-3 years: Less than 20 ng/dL Age 4-5 years: Less than 30 ng/dL Age 6-7 years: Less than 7 ng/dL Age 8-9 years: 1-11 ng/dL Age 10-11 years: 3-32 ng/dL Age 12-13 years: 6-50 ng/dL Age 14-15 years: 6-52 ng/dL Age 16-17 years: 9-58 ng/dL Age 18-59 years: 9-55 ng/dL Age 60 years and above: 5-32 ng/dL Premature (26-28 weeks): 5-16 ng/dL Premature (29-35 weeks): 5-22 ng/dL Premenopausal (Greater than 18 years): 9-55 ng/dL Postmenopausal: 5-32 ng/dL Tanner Stage I: 2-17 ng/dL Tanner Stage II: 5-40 ng/dL Tanner Stage III: 10-63 ng/dL Tanner Stage IV-V: 11-62 ng/dL
Testosterone, % Free (calculated)	%	Reference Intervals for Males: Age up to 18 years: Not Available Age 18 years and above: 1.6-2.9 % Reference Intervals for Females: Not Available

7610SP Testosterone, Free and Total (CSA), Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (84403): Testosterone, Total, Testosterone, Free (calculated), Testosterone, % Free (calculated)
Method (CPT Code): Colorimetry (None):
IA (84270): Sex Hormone Binding Globulin

Compound Name	Units	Reference Comment
Testosterone, Total	ng/dL	Reference Intervals for Males: Up to 1 month: 75-400 ng/dL Age 1-5 months: 14-363 ng/dL Age 6-24 months: Less than 37 ng/dL Age 2-3 years: Less than 15 ng/dL Age 4-5 years: Less than 19 ng/dL Age 6-7 years: Less than 13 ng/dL Age 8-9 years: 2-8 ng/dL Age 10-11 years: 2-165 ng/dL

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		Age 12-13 years: 3-619 ng/dL Age 14-15 years: 31-733 ng/dL Age 16-17 years: 158-826 ng/dL Age 18-39 years: 300-1080 ng/dL Age 40-59 years: 300-890 ng/dL Age 60 years and above: 300-720 ng/dL Premature (26-28 weeks): 59-125 ng/dL Premature (29-35 weeks): 37-198 ng/dL Tanner Stage I: 2-15 ng/dL Tanner Stage II: 3-303 ng/dL Tanner Stage III: 10-851 ng/dL Tanner Stage IV-V: 162-847 ng/dL Reference Intervals for Females: Up to 1 month: 20-64 ng/dL Age 1-5 months: Less than 20 ng/dL Age 6-24 months: Less than 9 ng/dL Age 2-3 years: Less than 20 ng/dL Age 4-5 years: Less than 30 ng/dL Age 6-7 years: Less than 7 ng/dL Age 8-9 years: 1-11 ng/dL Age 10-11 years: 3-32 ng/dL Age 12-13 years: 6-50 ng/dL Age 14-15 years: 6-52 ng/dL Age 16-17 years: 9-58 ng/dL Age 18-59 years: 9-55 ng/dL Age 60 years and above: 5-32 ng/dL Premature (26-28 weeks): 5-16 ng/dL Premature (29-35 weeks): 5-22 ng/dL Premenopausal (Greater than 18 years): 9-55 ng/dL Postmenopausal: 5-32 ng/dL Tanner Stage I: 2-17 ng/dL Tanner Stage II: 5-40 ng/dL Tanner Stage III: 10-63 ng/dL Tanner Stage IV-V: 11-62 ng/dL
Testosterone, % Free (calculated)	%	Reference Intervals for Males: Age up to 18 years: Not Available Age 18 years and above: 1.6-2.9 % Reference Intervals for Females: Not Available

7601SP Testosterone, Free and Total, Serum/Plasma

Test Updates

Test Changes

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (84403): Testosterone, Total, Testosterone, Free (calculated)
Method (CPT Code) Colorimetry (None):
IA (None):

Compound Name	Units	Reference Comment
Testosterone, Total	ng/dL	Reference Intervals for Males: Up to 1 month: 75-400 ng/dL Age 1-5 months: 14-363 ng/dL Age 6-24 months: Less than 37 ng/dL Age 2-3 years: Less than 15 ng/dL Age 4-5 years: Less than 19 ng/dL Age 6-7 years: Less than 13 ng/dL Age 8-9 years: 2-8 ng/dL Age 10-11 years: 2-165 ng/dL Age 12-13 years: 3-619 ng/dL Age 14-15 years: 31-733 ng/dL Age 16-17 years: 158-826 ng/dL Age 18-39 years: 300-1080 ng/dL Age 40-59 years: 300-890 ng/dL Age 60 years and above: 300-720 ng/dL Premature (26-28 weeks): 59-125 ng/dL Premature (29-35 weeks): 37-198 ng/dL Tanner Stage I: 2-15 ng/dL Tanner Stage II: 3-303 ng/dL Tanner Stage III: 10-851 ng/dL Tanner Stage IV-V: 162-847 ng/dL Reference Intervals for Females: Up to 1 month: 20-64 ng/dL Age 1-5 months: Less than 20 ng/dL Age 6-24 months: Less than 9 ng/dL Age 2-3 years: Less than 20 ng/dL Age 4-5 years: Less than 30 ng/dL Age 6-7 years: Less than 7 ng/dL Age 8-9 years: 1-11 ng/dL Age 10-11 years: 3-32 ng/dL Age 12-13 years: 6-50 ng/dL Age 14-15 years: 6-52 ng/dL Age 16-17 years: 9-58 ng/dL Age 18-59 years: 9-55 ng/dL Age 60 years and above: 5-32 ng/dL Premature (26-28 weeks): 5-16 ng/dL Premature (29-35 weeks): 5-22 ng/dL Premenopausal (Greater than 18 years): 9-55 ng/dL

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		Postmenopausal: 5-32 ng/dL Tanner Stage I: 2-17 ng/dL Tanner Stage II: 5-40 ng/dL Tanner Stage III: 10-63 ng/dL Tanner Stage IV-V: 11-62 ng/dL

7613SP Testosterone, Free, Total and Bioavailable (CSA), Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (84403): Testosterone, Total, Testosterone, Free (calculated),
Method (CPT Code) Testosterone, % Free (calculated), Testosterone, Bioavailable (calculated)
Colorimetry (None):
IA (84270): Sex Hormone Binding Globulin

Compound Name	Units	Reference Comment
Testosterone, Total	ng/dL	Reference Intervals for Males: Up to 1 month: 75-400 ng/dL Age 1-5 months: 14-363 ng/dL Age 6-24 months: Less than 37 ng/dL Age 2-3 years: Less than 15 ng/dL Age 4-5 years: Less than 19 ng/dL Age 6-7 years: Less than 13 ng/dL Age 8-9 years: 2-8 ng/dL Age 10-11 years: 2-165 ng/dL Age 12-13 years: 3-619 ng/dL Age 14-15 years: 31-733 ng/dL Age 16-17 years: 158-826 ng/dL Age 18-39 years: 300-1080 ng/dL Age 40-59 years: 300-890 ng/dL Age 60 years and above: 300-720 ng/dL Premature (26-28 weeks): 59-125 ng/dL Premature (29-35 weeks): 37-198 ng/dL Tanner Stage I: 2-15 ng/dL Tanner Stage II: 3-303 ng/dL Tanner Stage III: 10-851 ng/dL Tanner Stage IV-V: 162-847 ng/dL Reference Intervals for Females: Up to 1 month: 20-64 ng/dL Age 1-5 months: Less than 20 ng/dL Age 6-24 months: Less than 9 ng/dL Age 2-3 years: Less than 20 ng/dL Age 4-5 years: Less than 30 ng/dL Age 6-7 years: Less than 7 ng/dL Age 8-9 years: 1-11 ng/dL

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		Age 10-11 years: 3-32 ng/dL Age 12-13 years: 6-50 ng/dL Age 14-15 years: 6-52 ng/dL Age 16-17 years: 9-58 ng/dL Age 18-59 years: 9-55 ng/dL Age 60 years and above: 5-32 ng/dL Premature (26-28 weeks): 5-16 ng/dL Premature (29-35 weeks): 5-22 ng/dL Premenopausal (Greater than 18 years): 9-55 ng/dL Postmenopausal: 5-32 ng/dL Tanner Stage I: 2-17 ng/dL Tanner Stage II: 5-40 ng/dL Tanner Stage III: 10-63 ng/dL Tanner Stage IV-V: 11-62 ng/dL
Testosterone, % Free (calculated)	%	Reference Intervals for Males: Age up to 18 years: Not Available Age 18 years and above: 1.6-2.9 % Reference Intervals for Females: Not Available

7614SP Testosterone, Free, Total and Bioavailable (CSA), Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (84403): Testosterone, Total, Testosterone, Free (calculated),
Method (CPT Code) Testosterone, % Free (calculated), Testosterone, Bioavailable (calculated)
Colorimetry (None):
IA (84270): Sex Hormone Binding Globulin

Compound Name	Units	Reference Comment
Testosterone, Total	ng/dL	Reference Intervals for Males: Up to 1 month: 75-400 ng/dL Age 1-5 months: 14-363 ng/dL Age 6-24 months: Less than 37 ng/dL Age 2-3 years: Less than 15 ng/dL Age 4-5 years: Less than 19 ng/dL Age 6-7 years: Less than 13 ng/dL Age 8-9 years: 2-8 ng/dL Age 10-11 years: 2-165 ng/dL Age 12-13 years: 3-619 ng/dL Age 14-15 years: 31-733 ng/dL Age 16-17 years: 158-826 ng/dL Age 18-39 years: 300-1080 ng/dL Age 40-59 years: 300-890 ng/dL Age 60 years and above: 300-720 ng/dL

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		Premature (26-28 weeks): 59-125 ng/dL Premature (29-35 weeks): 37-198 ng/dL Tanner Stage I: 2-15 ng/dL Tanner Stage II: 3-303 ng/dL Tanner Stage III: 10-851 ng/dL Tanner Stage IV-V: 162-847 ng/dL Reference Intervals for Females: Up to 1 month: 20-64 ng/dL Age 1-5 months: Less than 20 ng/dL Age 6-24 months: Less than 9 ng/dL Age 2-3 years: Less than 20 ng/dL Age 4-5 years: Less than 30 ng/dL Age 6-7 years: Less than 7 ng/dL Age 8-9 years: 1-11 ng/dL Age 10-11 years: 3-32 ng/dL Age 12-13 years: 6-50 ng/dL Age 14-15 years: 6-52 ng/dL Age 16-17 years: 9-58 ng/dL Age 18-59 years: 9-55 ng/dL Age 60 years and above: 5-32 ng/dL Premature (26-28 weeks): 5-16 ng/dL Premature (29-35 weeks): 5-22 ng/dL Premenopausal (Greater than 18 years): 9-55 ng/dL Postmenopausal: 5-32 ng/dL Tanner Stage I: 2-17 ng/dL Tanner Stage II: 5-40 ng/dL Tanner Stage III: 10-63 ng/dL Tanner Stage IV-V: 11-62 ng/dL
Testosterone, % Free (calculated)	%	Reference Intervals for Males: Age up to 18 years: Not Available Age 18 years and above: 1.6-2.9 % Reference Intervals for Females: Not Available

7602SP Testosterone, Free, Total and Bioavailable, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code)
LC-MS/MS (84403): Testosterone, Total, Testosterone, Free (calculated), Testosterone, Bioavailable (calculated)
Colorimetry (82040):
IA (84270): Sex Hormone Binding Globulin

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Testosterone, Total	ng/dL	Reference Intervals for Males: Up to 1 month: 75-400 ng/dL Age 1-5 months: 14-363 ng/dL Age 6-24 months: Less than 37 ng/dL Age 2-3 years: Less than 15 ng/dL Age 4-5 years: Less than 19 ng/dL Age 6-7 years: Less than 13 ng/dL Age 8-9 years: 2-8 ng/dL Age 10-11 years: 2-165 ng/dL Age 12-13 years: 3-619 ng/dL Age 14-15 years: 31-733 ng/dL Age 16-17 years: 158-826 ng/dL Age 18-39 years: 300-1080 ng/dL Age 40-59 years: 300-890 ng/dL Age 60 years and above: 300-720 ng/dL Premature (26-28 weeks): 59-125 ng/dL Premature (29-35 weeks): 37-198 ng/dL Tanner Stage I: 2-15 ng/dL Tanner Stage II: 3-303 ng/dL Tanner Stage III: 10-851 ng/dL Tanner Stage IV-V: 162-847 ng/dL Reference Intervals for Females: Up to 1 month: 20-64 ng/dL Age 1-5 months: Less than 20 ng/dL Age 6-24 months: Less than 9 ng/dL Age 2-3 years: Less than 20 ng/dL Age 4-5 years: Less than 30 ng/dL Age 6-7 years: Less than 7 ng/dL Age 8-9 years: 1-11 ng/dL Age 10-11 years: 3-32 ng/dL Age 12-13 years: 6-50 ng/dL Age 14-15 years: 6-52 ng/dL Age 16-17 years: 9-58 ng/dL Age 18-59 years: 9-55 ng/dL Age 60 years and above: 5-32 ng/dL Premature (26-28 weeks): 5-16 ng/dL Premature (29-35 weeks): 5-22 ng/dL Premenopausal (Greater than 18 years): 9-55 ng/dL Postmenopausal: 5-32 ng/dL Tanner Stage I: 2-17 ng/dL Tanner Stage II: 5-40 ng/dL Tanner Stage III: 10-63 ng/dL Tanner Stage IV-V: 11-62 ng/dL

Test Updates

Test Changes

7603SP Testosterone, Total and Bioavailable, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (84403): Testosterone, Total, Testosterone, Bioavailable (calculated)
Method (CPT Code) Colorimetry (82040):
IA (84270): Sex Hormone Binding Globulin

Compound Name	Units	Reference Comment
Testosterone, Total	ng/dL	Reference Intervals for Males: Up to 1 month: 75-400 ng/dL Age 1-5 months: 14-363 ng/dL Age 6-24 months: Less than 37 ng/dL Age 2-3 years: Less than 15 ng/dL Age 4-5 years: Less than 19 ng/dL Age 6-7 years: Less than 13 ng/dL Age 8-9 years: 2-8 ng/dL Age 10-11 years: 2-165 ng/dL Age 12-13 years: 3-619 ng/dL Age 14-15 years: 31-733 ng/dL Age 16-17 years: 158-826 ng/dL Age 18-39 years: 300-1080 ng/dL Age 40-59 years: 300-890 ng/dL Age 60 years and above: 300-720 ng/dL Premature (26-28 weeks): 59-125 ng/dL Premature (29-35 weeks): 37-198 ng/dL Tanner Stage I: 2-15 ng/dL Tanner Stage II: 3-303 ng/dL Tanner Stage III: 10-851 ng/dL Tanner Stage IV-V: 162-847 ng/dL Reference Intervals for Females: Up to 1 month: 20-64 ng/dL Age 1-5 months: Less than 20 ng/dL Age 6-24 months: Less than 9 ng/dL Age 2-3 years: Less than 20 ng/dL Age 4-5 years: Less than 30 ng/dL Age 6-7 years: Less than 7 ng/dL Age 8-9 years: 1-11 ng/dL Age 10-11 years: 3-32 ng/dL Age 12-13 years: 6-50 ng/dL Age 14-15 years: 6-52 ng/dL Age 16-17 years: 9-58 ng/dL Age 18-59 years: 9-55 ng/dL Age 60 years and above: 5-32 ng/dL Premature (26-28 weeks): 5-16 ng/dL Premature (29-35 weeks): 5-22 ng/dL

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		Premenopausal (Greater than 18 years): 9-55 ng/dL Postmenopausal: 5-32 ng/dL Tanner Stage I: 2-17 ng/dL Tanner Stage II: 5-40 ng/dL Tanner Stage III: 10-63 ng/dL Tanner Stage IV-V: 11-62 ng/dL

7600SP Testosterone, Total, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (84403): Testosterone, Total
Method (CPT Code)

Compound Name	Units	Reference Comment
Testosterone, Total	ng/dL	Reference Intervals for Males: Up to 1 month: 75-400 ng/dL Age 1-5 months: 14-363 ng/dL Age 6-24 months: Less than 37 ng/dL Age 2-3 years: Less than 15 ng/dL Age 4-5 years: Less than 19 ng/dL Age 6-7 years: Less than 13 ng/dL Age 8-9 years: 2-8 ng/dL Age 10-11 years: 2-165 ng/dL Age 12-13 years: 3-619 ng/dL Age 14-15 years: 31-733 ng/dL Age 16-17 years: 158-826 ng/dL Age 18-39 years: 300-1080 ng/dL Age 40-59 years: 300-890 ng/dL Age 60 years and above: 300-720 ng/dL Premature (26-28 weeks): 59-125 ng/dL Premature (29-35 weeks): 37-198 ng/dL Tanner Stage I: 2-15 ng/dL Tanner Stage II: 3-303 ng/dL Tanner Stage III: 10-851 ng/dL Tanner Stage IV-V: 162-847 ng/dL Reference Intervals for Females: Up to 1 month: 20-64 ng/dL Age 1-5 months: Less than 20 ng/dL Age 6-24 months: Less than 9 ng/dL Age 2-3 years: Less than 20 ng/dL Age 4-5 years: Less than 30 ng/dL Age 6-7 years: Less than 7 ng/dL Age 8-9 years: 1-11 ng/dL Age 10-11 years: 3-32 ng/dL

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		Age 12-13 years: 6-50 ng/dL Age 14-15 years: 6-52 ng/dL Age 16-17 years: 9-58 ng/dL Age 18-59 years: 9-55 ng/dL Age 60 years and above: 5-32 ng/dL Premature (26-28 weeks): 5-16 ng/dL Premature (29-35 weeks): 5-22 ng/dL Premenopausal (Greater than 18 years): 9-55 ng/dL Postmenopausal: 5-32 ng/dL Tanner Stage I: 2-17 ng/dL Tanner Stage II: 5-40 ng/dL Tanner Stage III: 10-63 ng/dL Tanner Stage IV-V: 11-62 ng/dL

8102B Therapeutic and Abused Drugs with Alcohol Screen, Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8102FL Therapeutic and Abused Drugs with Alcohol Screen, Fluid (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

Test Updates

Test Changes

8102SP Therapeutic and Abused Drugs with Alcohol Screen, Serum/Plasma (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	Therapeutic serum range: 10 - 35 mcg/mL. This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8102TI Therapeutic and Abused Drugs with Alcohol Screen, Tissue (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/g	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).

8102U Therapeutic and Abused Drugs with Alcohol Screen, Urine (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
10-Hydroxycarbazepine	mcg/mL	This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepinen in patients who have taken Eslicarbazepine Acetate (Aptiom®).